Research Article| Volume 15, ISSUE 5, P377-381, December 2011

Download started.


The late complications of totally implantable central venous access ports: The results from an Italian multicenter prospective observation study

  • Alberto Dal Molin
    Corresponding author.
    Nursing School, Biella Hospital, University of Piemonte Orientale, Italy
    Search for articles by this author
  • Laura Rasero
    University of Florence, Italy
    Search for articles by this author
  • Linda Guerretta
    Oncology Outpatient Biella Hospital, Italy
    Search for articles by this author
  • Elisa Perfetti
    Oncology Center of Biella, Italy
    Search for articles by this author
  • Mario Clerico
    Oncology Center of Biella, Italy
    Search for articles by this author
  • Author Footnotes
    ☆ Working Group: Day Hospital di Oncologia - Biella: Andrea Rabbachin, Barbara Sartorello, Anna Cavagnetto; Day Hospital dell’Ospedale Maggiore della Carità di Novara: Gianfranca Solinas, Carmela Morgatico; Day Hospital Oncoematologico di Alessandria: Maria Grazia Candeo, Barbara Fadda; Centro oncoematologico subalpino (COES) - DH oncologia - AOU S. Giovanni Battista – Torino: Sabrina Pellachin, Silvana Storto; Day Hospital Oncologico CURO dell’ospedale Molinette di Torino: Maria Tropeano, Monika Nante; Medicina interna II ad indirizzo ematologico DH Ospedale San Luigi Gonzaga Orbassano (TO): Lorena Pilone, Concetta Bellia, Antonietta Mancino; S. C. D. U di Oncologia polmonare D.H. AOU S. Luigi Gonzaga Orbassano (TO): Vincenza Augello, Tiziana Martinatto, Giovanna Sapioli; Day Hospital Oncologia Medica Azienda Ospedaliera Universitaria San Luigi di Orbassano (TO): Piero Luigi Giuliano, Anna Rita Deluigi; Day Hospital Onco-Ematologico A.S.O. Ospedale Mauriziano Umberto I Torino: Daniela Ballaminut; Day Hospital Oncologico dell’Istituto di Ricerca e Cura del Cancro (IRCC) di Candiolo (Torino): Anna Maria Ballari, Marina Caliciotti, Paola Culotta; Day Hospital Onco/ematologico Ospedale Cardinal Massaia - ASL AT ASTI: Sara Franceschi, Aldele Calori; Servizio di Oncologia Novi Ligure- ASL AL: Laura Giorcelli, Silvana Gatti, Anna Maria Percivale; Day Hospital Oncologico AO di Lodi: Loredana Granata, Alessandra Laurano; Istituto Oncologico Veneto: Grosso Daniela, Maria Padovan; Oncologia Medica sezione cure ULSS 6 Vicenza: Roberta Cimenton, Renza Valente, Gianmaria Fanchin; Day Hospital Oncologico Azienda Ospedaliera - Universitaria "Ospedali Riuniti" di Trieste: Anna Claudia di Venanzio, Laura Donat; Day Hospital di Ematologia e Oncologia Medica Istituto Seragnoli Azienda Ospedaliera S’Orsola-Malpighi Bologna: Giuliana Nepoti; Day Hospital Oncologia Medica Ospedale Versilia - ASL 12: Lucia Belli, Elena Landucci, Nicoletta Malacarne; Day Hospital Ematologia Adulti Pisa: Albiani Anna, AnnaMaria Bovicelli; Day Hospital Polo Oncologico di area vasta nord-ovest dell’Azienda Ospedaliero-Universitaria Pisana: Mario Forte, Federica Barsotti, Luca Pulizia; UO Oncologia Medica DH e Ambulatori del Presidio Ospedaliero di Livorno – USL 6: Alessio Petronici; Day Hospital Oncologia Medica dell’Ospedale di Cecina (Azienda USL 6 di Livorno): Simona Magazzini, Chiara Giannoni, Valentina Brogi; Day Hospital – Ambulatori Oncoematologici della Azienda Ospedaliera Universitaria Careggi di Firenze: Carla Landi, Jean Pierre Caruso; Day Hospital Oncologico della Azienda Ospedaliera Universitaria Careggi di Firenze: Daniele Pecoraro, Monica Marongiu, Luigi Ferragina; Clinica di Oncologia-Ospedali Riuniti di Ancona: Fabiana Marcucci, Stefania Vescovi; A.O.U.P. "Paolo Giaccone" di Palermo – Unità Operativa di Oncologia Medica: Anna Basile, Giovanni Gianfortuna, Carolina La Corte.
Published:December 17, 2010DOI:



      The principal aim of this study is to analyze the incidence of late complications in oncologic patients with totally implanted central venous access ports.


      A prospective multicenter observational study was conducted in 26 Italian oncologic outpatient clinics. 1076 cancer patients with Totally Implanted Central Venous Access Ports (TIAP) were observed. 515 devices were observed in patients under treatment and 561 in patients who went to the outpatient clinic only for flushing.


      Late complications observed in patients under treatment were: 3 pocket infections (0.09/1000 days of port observation), 1 cutaneous infection (0.03/1000 days of port observation), 8 occlusions (0.24/1000 days of port observation) and 12 others.
      In patients using the device only for flushing we observed 4 cases of device related bacteremia (0.04/1000 days of port observation), 1 pocket infection (0.01/1000 days of port observation), 1 cutaneous infection (0.01/1000 days of port observation), 3 occlusions (0.03/1000 days of port observation) and 7 other complications.


      The low incidence of complications suggests that TIAP is safe and reliable for long term intermittent venous access. Our results support the use of TIAP in the oncology patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Oncology Nursing
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Arch P.
        Port navigation: let the journey begin.
        Clinical Journal of Oncology Nursing. 2007; 11: 485-488
        • Biffi R.
        • Corrado F.
        • de Braud F.
        • et al.
        Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.
        European Journal of Cancer. 1997; 33: 1190-1194
        • Biffi R.
        • de Braud F.
        • Orsi F.
        • et al.
        Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
        Annals of Oncology. 1998; 9: 767-773
        • Biffi R.
        • Pozzi S.
        • Agazzi A.
        • et al.
        Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.
        Annals of Oncology. 2004; 15: 296-300
        • Dal Molin A.
        • Guerretta L.
        • Mazzufero F.
        • et al.
        The management of totally implanted venous ports in the ambulatory oncologic patient.
        The Journal of Vascular Access. 2009; 10: 22-26
        • Dougherty L.
        Maintaining vascular access devices: the nurse’s role.
        Support Care Cancer. 1998; 6: 23-30
        • Dougherty L.
        Central Venous Access Devices – Care and Management.
        Blackwell Publishing, Oxford2006
        • Gallieni M.
        • Pittiruti M.
        • Biffi R.
        Vascular access in oncology patients.
        A Cancer Journal for Clinicians. 2008; 58: 323-346
        • Halderman F.
        Selecting a vascular access device.
        Nursing. 2000; 30: 59-61
        • Kuo Y.S.
        • Schwartz B.
        • Santiago J.
        • et al.
        How often should a port-A-cath be flushed?.
        Cancer Investigation. 2005; 23: 582-585
        • Maki D.G.
        • Kluger D.M.
        • Crnich C.J.
        The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies.
        Mayo Clinic Proceedings. 2006; 81: 1159-1171
        • Marschall J.
        • Mermel L.A.
        • Classen D.
        • et al.
        Strategies to prevent central line-associated bloodstream infections in acute care hospitals.
        Infection Control and Hospital Epidemiology. 2008; 29: S22-S30
        • NICE Guidelines
        • NHS National Institute for Clinical Excellence Infection Control
        Prevention of Healthcare Associated Infection in Primary and Community Care.
        2003 (London)
        • Niederhuber J.E.
        • Ensminger W.
        • Gyves J.W.
        • et al.
        Totally implanted venous and arterial access system to replace external catheter in cancer treatment.
        Surgery. 1982; 92: 706-712
        • O’Grady N.P.
        • Alexander M.
        • Dellinger E.P.
        • et al.
        Guidelines for the prevention of intravascular catheter – Related infections.
        Infection Control and Hospital Epidemiology. 2002; 23: 759-769
        • Pittiruti M.
        • Hamilton H.
        • Biffi R.
        • et al.
        ESPEN guidelines on parenteral nutrition: central venous catheters (access, care, diagnosis and therapy of complications).
        Clinical Nutrition. 2009; 28 (2009): 365-377
        • Pratt R.J.
        • Pellowe C.M.
        • Wilson J.A.
        • et al.
        Epic2: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.
        The Journal of Hospital Infection. 2007; 65: S1-S64
        • Registered Nurses Association of Ontario (RNAO)
        Assessment and Device Selection for Vascular Access, Nursing Best Practice Guideline.
        • Registered Nurses Association of Ontario (RNAO)
        Care and Maintenance to Reduce Vascular Access Complication, Nursing Best Practice Guideline.
        • RCN Standards
        Royal College of Nurses: Standards for Infusion Therapy.
        • Vescia S.
        • Baumgärtner A.K.
        • Jacobs V.R.
        • et al.
        Management of venous port systems in oncology: a review of current evidence.
        Annals of Oncology. 2008; 19: 9-15
        • Yildizeli B.
        • Laçin T.
        • Batirel H.F.
        • et al.
        Complication and management of long-term central venous access catheters and ports.
        Journal of Vascular Access. 2004; 5: 174-178